← Back
Pharmacology I · Exam 3 · Class of 2028

Asthma and Chronic Obstructive Pulmonary Disease Drugs Compared by Class

Every respiratory drug class side by side: quick relief or long-term controller, how it works, what it causes and what to teach. Smoking cessation agents are at the end. No doses.

Lecture 11 — Drugs for Pulmonary Infections, Asthma and Chronic Obstructive Pulmonary Disease 15 rows

Read the second column first. The quick-relief drugs are the short-acting beta-2 agonists, the anticholinergics and the systemic corticosteroids; everything else is a long-term controller taken daily whether or not the patient feels well. Two never-alone rules: a long-acting beta-2 agonist is never used alone in asthma (hence the combination inhalers), and the mast cell stabilizers must be taken before the exposure. Chronic obstructive pulmonary disease by group (slide 102): group A a short-acting bronchodilator as needed; group B a long-acting muscarinic antagonist or long-acting beta-2 agonist; group C a long-acting muscarinic antagonist; group D a long-acting muscarinic antagonist, or both long-acting bronchodilators with severe breathlessness, or an inhaled glucocorticoid with a long-acting beta-2 agonist when asthma overlaps; every group avoids smoking and gets influenza and pneumococcal vaccines. Current guidelines differ: the 2023 report merged groups C and D into group E. Doses are not tested and are left out.
Class and drugsQuick relief or controllerMechanismAdverse effectsCautions and educationSource
Short-acting beta-2 agonists
albuterol (ProAir, Ventolin), levalbuterol (Xopenex)
Quick relief; work rapidly, last 4 to 6 hoursRaise cAMP (cyclic adenosine monophosphate), which inhibits myosin light chain kinase and relaxes airway smooth muscleTachycardia, hypotension, headache, dizziness, insomnia, tremor, hyperglycemiaUse sparingly: overuse means poor control; wait 15 to 30 seconds between puffsL11
slide 70
slide 68
slide 69
slide 71
slide 98
Long-acting beta-2 agonists
formoterol (Foradil), salmeterol (Serevent)
Controller; last 12 hours or moreSame as the short-acting drugs (cyclic adenosine monophosphate up, smooth muscle relaxed)As for the short-acting drugs: increased heart rate, tremorNever alone for asthma: only with an inhaled corticosteroidL11
slide 70
slide 68
Inhaled corticosteroids
beclomethasone, budesonide, flunisolide, fluticasone, mometasone, triamcinolone
ControllerInhibit the inflammatory cascade; lower bronchial responsiveness long termOral candidiasis (thrush); growth suppression in children at high dose; immune inhibition (systemic action)Up to 8 weeks for maximal effect: take dailyL11
slide 73
slide 72
slide 67
Combination inhalers
Symbicort, Dulera, Advair
ControllerFormoterol/budesonide (Symbicort), formoterol/mometasone (Dulera), salmeterol/fluticasone (Advair): a long-acting beta-2 agonist plus an inhaled corticosteroidThose of the two componentsThe way a long-acting beta-2 agonist is used in asthmaL11
slide 74
Leukotriene modifier
montelukast (Singulair)
Controller; oralLeukotriene D4 receptor (cysteinyl leukotriene 1 receptor) antagonist; that receptor mediates inflammation, bronchial constriction and mucus secretionListed as minimal and well tolerated. Current labeling differs: an FDA (Food and Drug Administration) boxed warning for neuropsychiatric events.Effective in aspirin-induced asthmaL11
slide 75
slide 61
slide 67
Mast cell stabilizers
cromolyn sodium, nedocromil (Tilade)
Controller; inhaled; limited useStabilize mast cells to remove the trigger or antigen; mechanism unknown (may interfere with calcium)None listedMust be taken before the antigen insult; up to 4 weeks to work, so take regularlyL11
slide 78
slide 77
Anti-immunoglobulin E antibody
omalizumab (Xolair)
Controller; subcutaneous every 2 to 4 weeksBinds circulating immunoglobulin E, decreasing high-affinity receptors on mast cells and preventing degranulationAnaphylaxis, urticaria, gastrointestinal disturbances, neutralizing antibodies, secondary malignancies, injection-site pain, bruisingWatch after each injectionL11
slide 79
slide 80
Other biologics
mepolizumab, benralizumab, reslizumab; dupilumab
Controller (step 5 add-on)Anti-interleukin-5 (mepolizumab, benralizumab, reslizumab; reslizumab given intravenously); anti-interleukin-4 (dupilumab)Similar to omalizumabFor the eosinophilic phenotype (blood eosinophils above 150 per microliter)L11
slide 81
slide 90
Methylxanthines
theophylline (aminophylline intravenously)
Controller; limited use; used in chronic obstructive pulmonary diseaseInhibits phosphodiesterase (types 4 and 5), raising cyclic adenosine monophosphate and cyclic guanosine monophosphate; adenosine receptor (A2B) antagonist; anti-inflammatory in the late responseArrhythmias, convulsions, headache, nausea, insomnia, heartburn; gastric acid stimulation; diuresisNarrow therapeutic index: monitor plasma levels. Less effective and less well tolerated than long-acting bronchodilators. The slides call it renally eliminated; it is mainly metabolized by the liver.L11
slide 83
slide 82
slide 84
slide 85
Short-acting anticholinergic
ipratropium (Atrovent)
Quick relief; up to 8 hoursBlocks acetylcholine at muscarinic receptors: bronchodilationAnticholinergic: blurry vision, dry mouth and eyes, flushing, fever, constipation, urinary retention, tachycardia, deliriumTeach the dry mouth and urinary retention to reportL11
slide 86
slide 87
slide 67
Long-acting anticholinergic
tiotropium (Spiriva)
Controller; 24 hours or moreSame muscarinic block as ipratropiumSame anticholinergic profileThe slides disagree: marked for chronic obstructive pulmonary disease only on the anticholinergic list, yet listed as an add-on at asthma steps 4 and 5.L11
slide 86
slide 90
Systemic corticosteroids
prednisone, prednisolone, methylprednisolone, dexamethasone
Quick relief for exacerbations; intravenous preferred in status asthmaticusSuppress, control and reverse airway inflammation; inhibit inflammatory cytokines; most potentAdrenal suppression, growth suppression, dermal thinning, hypertension, hyperglycemia, mood change, steroid myopathy, immunosuppressionLimited use because of side effects; taper a longer course (general rule given: more than 5 days; references differ)L11
slide 88
slide 89
slide 99
slide 67
Bupropion sustained release
Zyban
Smoking cessationInhibits norepinephrine and dopamine uptake, mimicking nicotine’s indirect activation of epinephrine and dopamine—Avoid with a seizure disorder or monoamine oxidase inhibitors; caution with tricyclic antidepressants and venlafaxineL11
slide 105
Nicotine replacement
patch, gum, spray, inhaler
Smoking cessation; 6 to 12 weeksReplaces nicotine: reduces craving and physical withdrawalTachyarrhythmias, hypertensionPatches and gum are over the counter; caution in cardiovascular diseaseL11
slide 106
slide 104
Varenicline
Chantix
Smoking cessation; 12 weeksPartial nicotine receptor agonist, to a lesser degree than nicotineNausea, sleep disturbance, headache; black box warning: neuropsychiatric events (depression, suicidal ideation)Start one week before the quit date. Current labeling differs: the boxed warning was removed in 2016.L11
slide 107